- Business Model
- B2B
- Website
- mondegobio.com
- Total Funding
- $22.3M
- Last Round
- $20.0M Series ASep 2025
- Rounds
- 2
About
Developing best-in-class PTPN2 inhibitors to advance breakthrough cancer immunotherapies with improved safety, tolerability, and efficacy.
Summary
Mondego Bio is a Biotech company based in Portugal. It has raised $22.3M in total across 2 rounds, most recently a $20.0M Series A round in Sep 2025. Investors include Biovance Capital, OrbiMed and Torrey Pines Investment.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Sep 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform